MASLD and HFpEF: Do We Need a Shared Treatment Strategy?
Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure with preserved ejection fraction (HFpEF) are increasingly recognised as manifestations of a shared cardiometabolic disorder. Driven by overlapping risk factors such as obesity and insulin resistance, these conditions frequently coexist and may interact through liver–heart crosstalk. Despite this, they are typically managed separately, with limited disease-specific therapies and suboptimal outcomes. In this podcast, we explore whether a more integrated approach could improve diagnosis, risk stratification, and treatment.
Host: Cyrielle Caussy (Lyon 1 University and Hospices Civils de Lyon)
Guests: Zannad Faiez (University of Lorraine, Nancy), Pinelopi Manousou (Imperial College London)
Prefer to listen on the go? This episode is also available on the following streaming platforms:
Talk Liver To Me is supported by Opella. Opella has had no input to the content of this programme.
This programme is intended for health are professionals only and is provided for educational purposes. EASL does not endorse or promote any medicinal products or medical devices. The views and opinions expressed are those of the speakers and do not necessarily reflect those of EASL.
COI:
Cyrielle Caussy: No COI to declare.
Faiez Zannad reports personal fees from Alnylam, Bayer, Biopeutics, Boehringer, Cellprothera, Centrix, Cereno, Cipla, Corteria, CVRx, Daiichi-Sankyo, HighTide, Lilly, Lupin, Merck, NodThera, NovoNordisk, Opalia Recordati, Owkin, Polygon, Ribocure, Roche, Viatris. Stock options or equities at Cereno pharmaceutical, founder of Cardiovascular Clinical Trialists (CVCT).
Pinelopi Manousou: No COI to declare.
EASL is not responsible for the accuracy of any translated versions of this podcast or of subtitles generated automatically by artificial intelligence.
